Monitoring After Pembrolizumab, Gemcitabine, and Cisplatin Treatment

Post-Treatment Surveillance Schedule

• Patients who have completed treatment with pembrolizumab, gemcitabine, and cisplatin require clinical and laboratory evaluation every 3 months during the first year, then every 6 months thereafter, with vigilant surveillance for immune-related adverse events that can develop even months after treatment cessation 1
• Clinical and biological evaluation should be performed every 3 months during the first year and every 6 months thereafter, with active seeking of occurrence or worsening of any symptoms related to immune-mediated toxicities 1

Required Laboratory Tests

• At each surveillance visit, obtain a laboratory panel including complete blood count (CBC), renal function tests, serum electrolytes, glycemia, coagulation studies, liver function tests, and thyroid-stimulating hormone (TSH) 1

Imaging Surveillance

• No routine imaging is recommended in the absence of symptoms, and imaging should only be performed when clinically indicated by new or worsening symptoms 1

Critical Immune-Related Adverse Events to Monitor

• Patients receiving pembrolizumab must be monitored very closely for immune-related adverse events throughout treatment and after completion, with the most common immune-related toxicities including pneumonitis, colitis, and endocrine toxicities 2, 3
• Monitor for new or worsening dyspnea, cough, or chest pain, and any respiratory symptoms should prompt immediate chest imaging 1
• Assess for changes in bowel habits, diarrhea, abdominal pain, or blood in stool, and consider colonoscopy for persistent diarrhea or colitis 1

Differential Diagnosis Approach

• When any new symptom occurs during or after treatment, consider three potential etiologies systematically: disease progression, fortuitous events, and treatment-related immune toxicity 1

Management of Suspected Immune-Related Adverse Events

• Any suspicious symptoms should lead to proper investigation, with the specific workup depending on the organ system involved, and follow ESMO clinical practice guidelines for management of toxicities from immunotherapy when immune-related adverse events are identified 1, 2, 3

Special Considerations for Combination Therapy

• The combination of pembrolizumab with gemcitabine and cisplatin does not introduce new safety signals beyond those expected from each agent individually, but the cumulative toxicity profile includes myelosuppression, nephrotoxicity, and immune-related adverse events 1, 2, 3